DE60317198D1 - Proteinkinaseinhibitoren - Google Patents
ProteinkinaseinhibitorenInfo
- Publication number
- DE60317198D1 DE60317198D1 DE60317198T DE60317198T DE60317198D1 DE 60317198 D1 DE60317198 D1 DE 60317198D1 DE 60317198 T DE60317198 T DE 60317198T DE 60317198 T DE60317198 T DE 60317198T DE 60317198 D1 DE60317198 D1 DE 60317198D1
- Authority
- DE
- Germany
- Prior art keywords
- protein kinase
- kinase inhibitors
- compound
- formula
- diastereomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPS251502 | 2002-05-23 | ||
AUPS2515A AUPS251502A0 (en) | 2002-05-23 | 2002-05-23 | Protein kinase inhibitors |
US39907002P | 2002-07-26 | 2002-07-26 | |
US399070P | 2002-07-26 | ||
PCT/AU2003/000629 WO2003099796A1 (en) | 2002-05-23 | 2003-05-23 | Protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60317198D1 true DE60317198D1 (de) | 2007-12-13 |
DE60317198T2 DE60317198T2 (de) | 2008-12-04 |
Family
ID=29585026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60317198T Expired - Lifetime DE60317198T2 (de) | 2002-05-23 | 2003-05-23 | Proteinkinaseinhibitoren |
Country Status (10)
Country | Link |
---|---|
US (2) | US7122550B2 (de) |
EP (1) | EP1513821B1 (de) |
CN (1) | CN100558715C (de) |
AT (1) | ATE377004T1 (de) |
CA (1) | CA2486183C (de) |
DE (1) | DE60317198T2 (de) |
GB (1) | GB2392154B (de) |
IL (2) | IL165264A0 (de) |
NZ (1) | NZ537155A (de) |
WO (1) | WO2003099796A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2490261A1 (en) * | 2002-06-27 | 2004-01-08 | The University Of Queensland | Differentiation modulating agents and uses therefor |
AU2002953255A0 (en) * | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
EP1644365A2 (de) * | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazin- und pyridinderivative als rho-kinase-inhibitoren |
US7390907B2 (en) | 2003-09-30 | 2008-06-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
PT2277865E (pt) | 2003-12-03 | 2015-02-05 | Ym Biosciences Australia Pty | Heterociclos de azoto de anel de 6 membros fenil substituídos como inibidores de polimerização de microtúbulos |
US20080194574A1 (en) * | 2003-12-16 | 2008-08-14 | Axxima Pharmaceuticals Ag | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases |
EP1807077B1 (de) * | 2004-10-22 | 2016-11-23 | Janssen Pharmaceutica NV | Inhibitoren von c-fms-kinase |
WO2006051311A1 (en) * | 2004-11-12 | 2006-05-18 | Galapagos Nv | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes |
GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
RS54181B9 (sr) | 2005-12-13 | 2020-01-31 | Incyte Holdings Corp | Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
AU2007240437B2 (en) | 2006-04-20 | 2012-12-06 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
NZ572072A (en) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
RU2009101911A (ru) * | 2006-06-22 | 2010-07-27 | Биовитрум Аб (Пабл) (Se) | Производные пиридина и пиразина в качестве ингибиторов mnk-киназы |
AU2007321719B2 (en) | 2006-11-15 | 2013-11-21 | Ym Biosciences Australia Pty Ltd | Inhibitors of kinase activity |
AU2013273769B2 (en) * | 2006-11-15 | 2016-05-12 | Ym Biosciences Australia Pty Ltd | Inhibitors of Kinase Activity |
CA2702650C (en) | 2007-03-12 | 2017-01-03 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
EP1992344A1 (de) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind |
MY154969A (en) | 2007-06-13 | 2015-08-28 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CA2701128A1 (en) | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
DK2252597T3 (da) * | 2008-02-01 | 2014-04-28 | Akinion Pharmaceuticals Ab | Pyrazinderivater og deres anvendelse som proteinkinaseinhibitorer |
MX2010012080A (es) * | 2008-05-05 | 2011-04-11 | Univ Winthrop Hospital | Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox. |
CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
US8652787B2 (en) | 2008-11-12 | 2014-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of ERBB4 as a prognostic and therapeutic marker for melanoma |
CN101475563B (zh) * | 2008-11-21 | 2012-11-14 | 东华大学 | 3-氨基-4-吲哚-n-甲基马来酰亚胺化合物、其制备及应用 |
MX2011012262A (es) | 2009-05-22 | 2012-01-25 | Incyte Corp | 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il] octano-o heptano-nitrilo como inhibidores de cinasas janus (jak). |
MY156727A (en) | 2009-05-22 | 2016-03-15 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2338888A1 (de) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridin-Derivate als JAK-Inhibitoren |
KR102283091B1 (ko) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
TWI499421B (zh) | 2010-05-21 | 2015-09-11 | Incyte Corp | Jak抑制劑的局部製劑 |
US9168297B2 (en) | 2010-06-23 | 2015-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (NRG-1) |
CA2818545C (en) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
BR112013012502A2 (pt) | 2010-11-19 | 2019-03-06 | Incyte Corporation | pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak |
CA2839437A1 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
US20150044178A1 (en) | 2011-12-28 | 2015-02-12 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
WO2014025675A1 (en) | 2012-08-07 | 2014-02-13 | Janssen Pharmaceutica Nv | Process for the preparation of heterocyclic ester derivatives |
KR20210037012A (ko) | 2012-11-15 | 2021-04-05 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
WO2014106606A1 (en) * | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
US20150352111A1 (en) * | 2013-01-10 | 2015-12-10 | Pulmokine, Inc. | Therapeutic Indications of Kinase Inhibitors |
AU2014205483B2 (en) | 2013-01-10 | 2017-11-30 | Gilead Sciences, Inc. | Non-selective kinase inhibitors |
NZ711976A (en) | 2013-03-06 | 2019-01-25 | Incyte Holdings Corp | Processes and intermediates for making a jak inhibitor |
SG10201801069QA (en) | 2013-08-07 | 2018-03-28 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
US9925184B2 (en) | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
CA2928626C (en) | 2013-11-14 | 2023-03-14 | The Doshisha | Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage |
MX2016007111A (es) | 2013-12-05 | 2016-08-11 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
TW202134236A (zh) | 2014-06-12 | 2021-09-16 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
KR20170129757A (ko) | 2015-03-25 | 2017-11-27 | 노파르티스 아게 | Fgfr4 억제제로서의 포르밀화 n-헤테로시클릭 유도체 |
JP2020500183A (ja) | 2016-10-27 | 2020-01-09 | プルモキネ、インコーポレイテッド | 肺高血圧症の治療のための併用療法 |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
EP3746429B1 (de) | 2018-01-30 | 2022-03-09 | Incyte Corporation | Verfahren zur herstellung von (1-(3-fluor-2-trifluormethyl)isonicotinyl)piperidin-4-on) |
EA202092343A1 (ru) | 2018-03-30 | 2021-01-20 | Инсайт Корпорейшн | Лечение гнойного гидраденита с использованием ингибиторов jak |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
JP3892296B2 (ja) * | 1999-09-10 | 2007-03-14 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
US20040102455A1 (en) | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
-
2003
- 2003-05-23 WO PCT/AU2003/000629 patent/WO2003099796A1/en active IP Right Grant
- 2003-05-23 DE DE60317198T patent/DE60317198T2/de not_active Expired - Lifetime
- 2003-05-23 CA CA2486183A patent/CA2486183C/en not_active Expired - Fee Related
- 2003-05-23 AT AT03727001T patent/ATE377004T1/de not_active IP Right Cessation
- 2003-05-23 GB GB0318438A patent/GB2392154B/en not_active Expired - Lifetime
- 2003-05-23 NZ NZ537155A patent/NZ537155A/en not_active IP Right Cessation
- 2003-05-23 IL IL16526403A patent/IL165264A0/xx unknown
- 2003-05-23 EP EP03727001A patent/EP1513821B1/de not_active Expired - Lifetime
- 2003-05-23 CN CNB038117355A patent/CN100558715C/zh not_active Expired - Fee Related
- 2003-05-23 US US10/469,303 patent/US7122550B2/en not_active Expired - Lifetime
-
2004
- 2004-11-16 IL IL165264A patent/IL165264A/en active IP Right Grant
-
2006
- 2006-03-02 US US11/367,248 patent/US20060148824A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003099796A1 (en) | 2003-12-04 |
US20040235862A1 (en) | 2004-11-25 |
IL165264A (en) | 2011-07-31 |
EP1513821B1 (de) | 2007-10-31 |
DE60317198T2 (de) | 2008-12-04 |
US20060148824A1 (en) | 2006-07-06 |
GB0318438D0 (en) | 2003-09-10 |
IL165264A0 (en) | 2005-12-18 |
CN100558715C (zh) | 2009-11-11 |
EP1513821A4 (de) | 2006-05-03 |
CA2486183C (en) | 2012-01-10 |
CA2486183A1 (en) | 2003-12-04 |
NZ537155A (en) | 2006-09-29 |
US7122550B2 (en) | 2006-10-17 |
GB2392154A (en) | 2004-02-25 |
GB2392154B (en) | 2005-01-19 |
ATE377004T1 (de) | 2007-11-15 |
EP1513821A1 (de) | 2005-03-16 |
CN1656082A (zh) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60317198D1 (de) | Proteinkinaseinhibitoren | |
ATE457025T1 (de) | Kinaseinhibitoren | |
SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
NO20054195D0 (no) | Isoksazolforbindelser som inhibitorer for varmesjokkproteiner | |
EA200501009A1 (ru) | Замещённые пирролопиразольные производные в качестве ингибиторов киназы | |
DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
NO20005237L (no) | Heterocyklisk substituerte amider anvendt som calpain- inhibitorer | |
ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
EA200301276A1 (ru) | Новые производные сульфоновых кислот | |
BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
DE602004005881D1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
EA200600898A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
NO20061302L (no) | Derivater av hydroksaminsyre som metalloproteinseinbitorer | |
EA200501900A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200501925A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200301101A1 (ru) | Производные пиперазина и их применение в качестве ингибиторов pde4 | |
NO20030297D0 (no) | Aryl sulfonamider som serotoninantagonist for behandling av fedme | |
EA200600455A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200600456A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200600454A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
EA200601086A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
CY1105789T1 (el) | Νεα μεθοδος για τη συνθεση πepιντοπριλ και των φαρμακευτικως αποδεκτων αλατων αυτου | |
NO20060922L (no) | Ny fremgangsmate for syntesen av perindopril og dens farmasoytiske akseptable salter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: CYTOPIA RESEARCH PTY. LTD., RICHMOND, VICTORIA, AU |
|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: YM BIOSCIENCES AUSTRALIA PTY LTD, MELBOURNE, V, AU |